The SARS-CoV-2 virus responsible for coronavirus 2019 (COVID-19) poses a significant challenge to healthcare systems worldwide. According to the World Health Organization (WHO), the outbreak of COVID-19 has been a pandemic that infected more than 25.32 million people and caused more than 848.25 thousand deaths worldwide at the time of 1st September 2020. Despite governmental initiatives aimed to contain the spread of the disease, several countries are experiencing unmanageable increases in medical equipment and larger testing capacity. The current diagnosis based on nuclear acid requires specialized instruments, time-consuming, and laborious, the low-cost and convenient technologies were still urgently needed. Both spike and nucleocapsid are key structural proteins of COVID-19 with good immunogenicity, can serve as primary targets for immunoassay. After comparative research, we certified nucleocapsid antigen-monoclonal antibody (mAbs) system was more suitable for the COVID-19 immunodetection. Subsequently, we designed a rapid test strip based on it that can be used in large-scale screening of COVID-19 in population and more suitable for some remote and special needs areas were restricted by a medical condition or for quick and large quantities of screenings.

导致 2019 年冠状病毒 (COVID-19) 的 SARS-CoV-2 病毒对全球医疗保健系统构成了重大挑战。根据世界卫生组织 (WHO) 的数据，截至 2020 年 9 月 1 日，COVID-19 的爆发已成为全球范围内感染超过 2532 万人并造成超过 84825 万人死亡的大流行病。尽管政府采取措施遏制疫情随着疾病的传播，一些国家的医疗设备和检测能力都在急剧增加。目前基于核酸的诊断需要专门的仪器，费时费力，仍迫切需要低成本、便捷的技术。spike 和 nucleocapsid 都是 COVID-19 的关键结构蛋白，具有良好的免疫原性，可以作为免疫测定的主要靶点。经过比较研究，我们证明核衣壳抗原-单克隆抗体（mAbs）系统更适合COVID-19免疫检测。随后，我们在其基础上设计了一种快速检测试纸，可用于人群中COVID-19的大规模筛查，更适用于一些偏远和特殊需求地区受医疗条件限制或快速大批量筛查。 .